Circulating adiponectin regulates serum C – reactive protein and Interleukine-6 in obesity

Paper Details

Research Paper 01/10/2011
Views (407) Download (12)

Circulating adiponectin regulates serum C – reactive protein and Interleukine-6 in obesity

Eizadi Mojtaba, Khorshidi Davood, Dooaly Hussein, Samarikhalaj Hamidreza
J. Bio. Env. Sci.1( 5), 89-96, October 2011.
Certificate: JBES 2011 [Generate Certificate]


Impaired adiposity-secreted adipocytokines is known to be associated with obesity and related diseases. The aim of this study was to assess the association between antiinflammatory cytokine adiponectin with C-reactive protein and interleukine-6 as two important pro-inflammatory cytokine in thirty nine sedentary healthy obese men aged 35 – 45 years. For this purpose, venous blood samples were collected from each subject after overnight fast in order to measuring serum adiponectin, CRP and Il-6. All anthropometrical variables were also measured. Pearson correlations were used to establish the relationship between adiponectin concentration with CRP and Il-6 in studied subjects. A significant negative correlation was observed between adiponectin (p = 0.022, r = 0.37) and Il-6 (p = 0.009, r = 0.41). Our data suggests that high adiponectin is associated low pro-inflammatory cytokine. We can say Serum adiponectin may affects circulating CRP an Il-6 as two inflammatory mediators and markers of increased cardiovascular risk.


Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J. 1999. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257, 79– 83.

Baratta R, Amato S, Degano C, Farina MG, Patanè G, Vigneri R, Frittitta L. 2004. Adiponectin Relationship with Lipid Metabolism Is Independent of Body Fat Mass: Evidence from Both Cross-Sectional and Intervention Studies. J Clin Endocrinol Metab 89(6), 2665-71.

Charles P. Lambert, Nicole R. Wright, Brian N. Finck, and Dennis T. Villareal. 2008. Exercise but not diet-induced weight loss decreases skeletal muscle inflammatory gene expression in frail obese elderly persons. J Appl Physiol 105, 473–478.

Fantuzzi G. 2005. Adipose tissue, adipokines, and inflammation. J. Allergy Clin. Immunol 115, 911–9.

Fried SK, Bunkin DA, Greenberg AS. 1998. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83:847-50.

Gibbs J, Young RC, Smith GP. 1973. Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 84, 488–495.

Grimble RF. 2003. Inflammatory response in the elderly. Curr Opin Clin Nutr Metab Care 6, 21–29.

Julia W, Karen C, Javier R, Ascension M. 2010. Role of physical activity on immune function Physical activity, exercise and low-grade systemic inflammation. Proceedings of the Nutrition Society 69, 400–406.

Kantartzis K, Rittig K, Balletshofer B, Machann J, Schick F, Porubska K. 2006. The Relationships of Plasma Adiponectin with a Favorable Lipid Profile, Decreased Inflammation, and Less Ectopic Fat Accumulation Depend on Adiposity. Clin Chem 52(10), 1934-42.

Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani H. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8,731–737.

Mantzoros CS, Li T, Manson JAE, Meigs JB, Hu FB. 2005. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. J Clin Endocrinol Metab 90, 4542–8.

Meilleur KG, Doumatey A, Huang H, Charles B, Chen G, Zhou J. 2010. Circulating adiponectin is associated with obesity and serum lipids in West Africans. J Clin Endocrinol Metab 95(7), 3517-21.

Moschen AR, Molnar C, Geiger S, Graziadei I, Ebenbichler CF, Weiss H. 2010. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor {alpha} expression. Gut 59(9), 1259-64.

Ouchi N, Kihara S, Arita Y. 1999. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100, 2473-6.

Ouchi N, Kihara S, Arita Y. 1999. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100, 2473–2476.

Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas E, Stefanadis C. 2008. Five-year incidence of cardiovascular disease and its predictors in Greece: the ATTICA study. Vasc Med 13, 113–21.

Pate RR, Pratt M, Blair SN. 1995. Physical activity and public health. A recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 273, 402–407.

Pearson TA, Mensah GA, Alexander RW. 2003. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499–511.

Peña AS, Belobrajdic DP, Wiltshire E, Gent R, Hirte C, Couper J. 2010. Adiponectin relates to smooth muscle function and folate in obese children. Int J Pediatr Obes 5(2), 185-91.

Philippou A, Bogdanis G, Maridaki M. 2009. Systemic cytokine response following exercise-induced muscle damage in humans. Clin Chem Lab Med 47, 777–782.

Reuben DB, Cheh AI, Harris TB, Ferrucci L, Rowe JW, Tracy RP. 2002. Peripheral blood markers of inflammation predict mortality and functional decline in high-functioning community-dwelling older persons. J Am Geriatr Soc 50, 638– 644.

Rotter V, Nagaev I, Smith U. 2003. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278, 45777-84.

Ryan   TJ,    Faxon    DP,   Gunnar    RM.   1988. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment on Diagnostic and Therapeutic Cardiovascular Procedures. Circulation 78, 486-502.

Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. 1996. The expression of TNF alpha by human muscle. Relationship to insulin resistance. J Clin Invest 97, 1111–1116.

Saltiel AR. 2001. You are what you secrete. Nat Med 7, 887–888.

Schulze MB, Rimm EB, Shai I, Rifai N, Hu FB. 2004. Relationship between adiponectin and glycemic control, blood lipids and inflammatory markers in men with type 2 diabetes. Diabetes Care 27, 1680–7.

Schwartz MW, Woods SC, Porte Jr D, Seeley RJ, Baskin DG. 2000. Central nervous systemcontrol of food intake. Nature 404, 661–671.

Shetty GK, Economides PA, Horton ES, Mantzoros C, Veves A. 2004. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27, 2450–7.

Simpson KA, Singh MA. 2008. Effects of exercise on adiponectin: a systematic review. Obesity (Silver Spring) 16(2), 241-56.

Spiegelman BM, Flier JS. 2001. Obesity and the regulation of energy balance. Cell 104, 531–543.

Spranger J, Verma S, Göhring I, Bobbert T, Seifert J, Sindler AL. 2006. Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes 55(1), 141-7.

Statnick MA, Beavers LS, Conner LJ. 2000. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res 1, 81-8.

Stefan N, Stumvoll M. 2002. Adiponectin—its role in metabolism and beyond. Horm Metab Res 34, 469–474.

Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, LazarMA. 2001. The hormone resistin links obesity to diabetes. Nature 409, 307–312.

Sun H, Zhang Y, Gao P, Li Q, Sun Y, Zhang J, Xu C. 2011. Adiponectin reduces C-reactive protein expression and downregulates STAT3 phosphorylation induced by IL-6 in HepG2 cells. Mol Cell Biochem 347(1-2), 183-9.

Tan Y, Peng X, Wang F, You Z, Dong Y, Wang S. 2006. Effects of tumor necrosis factor-alpha on the 26S proteasome and 19S regulator in skeletal muscle of severely scalded mice. J Burn Care Res 27, 226–233.

Trayhurn P & Wood IS. 2004. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92, 347–355.

Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, Staiger H. 2003. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52, 239–243.

Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE. 2001. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86, 1930–1935.

Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K,. 2002. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 103, 137–42.

Yamauchi T, Kamon J, Minokoshi Y. 2002. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8, 1288–1295.

Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K. 2003. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278, 2461–2468.

Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. 2000. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148, 209–14.